Core Viewpoint - The company has established a special settlement account for cash management of idle raised funds, allowing for the investment of up to 580 million RMB in low-risk, liquid financial products to enhance fund utilization efficiency [2][6]. Group 1: Cash Management Account Establishment - The company has opened a special settlement account for cash management of idle raised funds, which will only be used for this purpose and will not store non-raised funds [3]. - The cash management aims to improve the efficiency of idle raised funds while ensuring the normal implementation of investment projects [6]. Group 2: Previous Cash Management Activities - The company previously utilized 100 million RMB to purchase financial products from Hangzhou Bank and Huaxia Bank, redeeming a total of 260 million RMB with annualized returns of 2.50% and 2.69% respectively [4]. Group 3: Current Cash Management Details - The current cash management involves an amount of 240 million RMB invested in a structured deposit product from Bohai Bank, with a management period from May 12, 2025, to November 11, 2025 [5][7]. Group 4: Approval and Oversight - The cash management proposal was approved in meetings held on October 25, 2024, by both the board of directors and the supervisory board, with consent from the supervisory institution [2][8]. - The company has established strict internal controls and oversight mechanisms to ensure compliance with regulations and effective risk management [8]. Group 5: Financial Impact - As of March 31, 2025, the company's debt-to-asset ratio stands at 17.27%, indicating a stable financial position while engaging in cash management activities [8]. - The principal from cash management will be recorded as "trading financial assets" on the balance sheet, with returns reflected in the profit statement as "investment income" [8].
湖北济川药业股份有限公司关于全资子公司开立募集资金现金管理专用结算账户并利用闲置募集资金进行现金管理的进展公告